Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 15Neoplasm Metastasis 3HER2-positive Breast Cancer 2Brain Neoplasms 2Stomach Neoplasms 1Solid Cancer 1Recurrence 1Rectal Neoplasms 1Neoplasms 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Liver Neoplasms 1Inflammatory Breast Neoplasms 1HER2-positive Early Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma 1Cancer Related Cognitive Decline 1Breast Neoplasms, Male 1Breast Diseases 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 12Cisplatin 5Cetuximab 5Paclitaxel 4durvalumab 3Nivolumab 3Ipilimumab 3Gemcitabine 3Cyclophosphamide 3poly ICLC 2avelumab 2Radiation 2Pemetrexed 2Leucovorin 2Irinotecan 2Fluorouracil 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tislelizumab 1tirbanibulin 1spartalizumab 1sonidegib 1sitravatinib 1repotrectinib 1pralsetinib 1pertuzumab 1pepinemab 1obinutuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma × pertuzumab × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡